Skip to main content
Erschienen in: World Journal of Urology 9/2017

14.02.2017 | Original Article

Perioperative morbidity, oncological outcomes and predictors of pT3a upstaging for patients undergoing partial nephrectomy for cT1 tumors

verfasst von: Pascal Mouracade, Onder Kara, Julien Dagenais, M. J. Maurice, R. J. Nelson, Ercan Malkoc, J. H. Kaouk

Erschienen in: World Journal of Urology | Ausgabe 9/2017

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To evaluate perioperative morbidity, oncological outcome and predictors of pT3a upstaging after partial nephrectomy (PN).

Materials and methods

Retrospective study of 1042 patients who underwent PN for cT1N0M0 renal cell carcinoma between 2007 and 2015. A total of 113 cT1 patients were upstaged to pT3a, while 929 were staged as pT1. Demographic, perioperative and pathological variables were reviewed. We compared the clinico-pathological characteristics, perioperative morbidity and oncological outcomes between pT3a and pT1 groups. Multivariate regression evaluates variables associated with T3a upstaging. Recurrence-free survival (RFS) and overall survival analyses were performed. Survival curves were compared using log-rank test.

Results

The pT3a tumors were high complexity tumors (median RENAL score 8 vs. 7, p < 0.01), higher hilar (h) location (27.5 vs. 14.8%, p < 0.01), higher grade (57.5 vs. 38.2%, p < 0.01), and higher positive surgical margins (18.6 vs. 5.8%, p < 0.01. Patients with pT3a had a higher estimated blood loss, transfusion rate, ischemia time and overall complications, though there were no differences in median e-GFR decline and major (Grade III-V) complications. Five-year RFS was 78.5% for pT3a group vs. 94.6% for pT1 group (log-rank p < 0.01). Male gender (OR 2.2, p < 0.01), and R.E.N.A.L. score (OR 2.3, p = 0.01) were preoperative predictors of upstaging. We acknowledge limitations in our study, most are inherent problems of retrospective studies.

Conclusion

Perioperative morbidity, after partial nephrectomy, is acceptable in cT1/pT3 tumors in comparison to cT1/pT1; however, upstaged patients had a worse oncological outcome. cT1/pT3a tumors are associated with adverse clinico-pathological features. Preoperative risk predictors of upstaging were higher R.E.N.A.L. score and male gender.
Literatur
1.
Zurück zum Zitat Weight CJ, Lythgoe C, Unnikrishnan R, Lane BR, Campbell SC, Fergany AF (2011) Partial nephrectomy does not compromise survival in patients with pathologic upstaging to pT2/pT3 or high-grade renal tumors compared with radical nephrectomy. Urology 77:1142–1146CrossRefPubMed Weight CJ, Lythgoe C, Unnikrishnan R, Lane BR, Campbell SC, Fergany AF (2011) Partial nephrectomy does not compromise survival in patients with pathologic upstaging to pT2/pT3 or high-grade renal tumors compared with radical nephrectomy. Urology 77:1142–1146CrossRefPubMed
2.
Zurück zum Zitat Nayak JG, Patel P, Saarela O et al (2016) Pathological upstaging of clinical T1 to pathological T3a renal cell carcinoma: a multi-institutional analysis of short-term outcomes. Urology 94:154–160CrossRefPubMed Nayak JG, Patel P, Saarela O et al (2016) Pathological upstaging of clinical T1 to pathological T3a renal cell carcinoma: a multi-institutional analysis of short-term outcomes. Urology 94:154–160CrossRefPubMed
3.
Zurück zum Zitat Hansen J, Sun M, Bianchi M et al (2012) Assessment of cancer control outcomes in patients with high-risk renal cell carcinoma treated with partial nephrectomy. Urology 80:347–353CrossRefPubMed Hansen J, Sun M, Bianchi M et al (2012) Assessment of cancer control outcomes in patients with high-risk renal cell carcinoma treated with partial nephrectomy. Urology 80:347–353CrossRefPubMed
4.
Zurück zum Zitat Ramaswamy K, Kheterpal E, Pham H et al (2015) Significance of pathologic T3a upstaging in clinical T1 renal masses undergoing nephrectomy. Clin Genitourin Cancer 13:344–349CrossRefPubMed Ramaswamy K, Kheterpal E, Pham H et al (2015) Significance of pathologic T3a upstaging in clinical T1 renal masses undergoing nephrectomy. Clin Genitourin Cancer 13:344–349CrossRefPubMed
5.
Zurück zum Zitat Roberts WW, Bhayani SB, Allaf ME, Chan TY, Kavoussi LR, Jarrett TW (2005) Pathological stage does not alter the prognosis for renal lesions determined to be stage T1 by computerized tomography. J Urol 173:713–715CrossRefPubMed Roberts WW, Bhayani SB, Allaf ME, Chan TY, Kavoussi LR, Jarrett TW (2005) Pathological stage does not alter the prognosis for renal lesions determined to be stage T1 by computerized tomography. J Urol 173:713–715CrossRefPubMed
6.
Zurück zum Zitat Gorin MA, Ball MW, Pierorazio PM et al (2013) Outcomes and predictors of clinical T1 to pathological T3a tumor up-staging after robotic partial nephrectomy: a multi-institutional analysis. J Urol 190:1907–1911CrossRefPubMed Gorin MA, Ball MW, Pierorazio PM et al (2013) Outcomes and predictors of clinical T1 to pathological T3a tumor up-staging after robotic partial nephrectomy: a multi-institutional analysis. J Urol 190:1907–1911CrossRefPubMed
7.
Zurück zum Zitat Kutikov A, Uzzo RG (2009) The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol 182:844 Kutikov A, Uzzo RG (2009) The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol 182:844
8.
Zurück zum Zitat Forbes CM, Rendon RA, Finelli A et al (2016) Disease progression and kidney function after partial vs. radical nephrectomy for T1 renal cancer. Urol Oncol 34(486):e17-486.e23 Forbes CM, Rendon RA, Finelli A et al (2016) Disease progression and kidney function after partial vs. radical nephrectomy for T1 renal cancer. Urol Oncol 34(486):e17-486.e23
9.
Zurück zum Zitat Badalato GM, Kates M, Wisnivesky JP, Choudhury AR, McKiernan JM (2012) Survival after partial and radical nephrectomy for the treatment of stage T1bN0M0 renal cell carcinoma (RCC) in the USA: a propensity scoring approach. BJU Int 109:1457–1462CrossRefPubMed Badalato GM, Kates M, Wisnivesky JP, Choudhury AR, McKiernan JM (2012) Survival after partial and radical nephrectomy for the treatment of stage T1bN0M0 renal cell carcinoma (RCC) in the USA: a propensity scoring approach. BJU Int 109:1457–1462CrossRefPubMed
10.
Zurück zum Zitat Maurice MJ, Zhu H, Kim SP, Abouassaly R (2016) Increased use of partial nephrectomy to treat high-risk disease. BJU Int 117:E75–E86CrossRefPubMed Maurice MJ, Zhu H, Kim SP, Abouassaly R (2016) Increased use of partial nephrectomy to treat high-risk disease. BJU Int 117:E75–E86CrossRefPubMed
11.
Zurück zum Zitat Lam JS, Klatte T, Patard JJ et al (2007) Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience. Eur Urol 52:155–162CrossRefPubMed Lam JS, Klatte T, Patard JJ et al (2007) Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience. Eur Urol 52:155–162CrossRefPubMed
12.
Zurück zum Zitat Chevinsky M, Imnadze M, Sankin A et al (2015) Pathological stage T3a significantly increases disease recurrence across all tumor sizes in renal cell carcinoma. J Urol 194:310–315CrossRefPubMedPubMedCentral Chevinsky M, Imnadze M, Sankin A et al (2015) Pathological stage T3a significantly increases disease recurrence across all tumor sizes in renal cell carcinoma. J Urol 194:310–315CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Margulis V, Tamboli P, Matin SF, Meisner M, Swanson DA, Wood CG (2007) Location of extrarenal tumor extension does not impact survival of patients with pT3a renal cell carcinoma. J Urol 178:1878–1882CrossRefPubMed Margulis V, Tamboli P, Matin SF, Meisner M, Swanson DA, Wood CG (2007) Location of extrarenal tumor extension does not impact survival of patients with pT3a renal cell carcinoma. J Urol 178:1878–1882CrossRefPubMed
14.
Zurück zum Zitat Saranchuk JW, Touijer AK, Hakimian P, Snyder ME, Russo P (2004) Partial nephrectomy for patients with a solitary kidney: the memorial Sloan-Kettering experience. BJU Int 94:1323–1328CrossRefPubMed Saranchuk JW, Touijer AK, Hakimian P, Snyder ME, Russo P (2004) Partial nephrectomy for patients with a solitary kidney: the memorial Sloan-Kettering experience. BJU Int 94:1323–1328CrossRefPubMed
15.
Zurück zum Zitat Kutikov A, Smaldone MC, Egleston BL et al (2011) Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL nephrometry score. Eur Urol 60:241–248CrossRefPubMedPubMedCentral Kutikov A, Smaldone MC, Egleston BL et al (2011) Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL nephrometry score. Eur Urol 60:241–248CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Halverson SJ, Kunju LP, Bhalla R et al (2013) Accuracy of determining small renal mass management with risk stratified biopsies: confirmation by final pathology. J Urol 189(2):441–446CrossRefPubMed Halverson SJ, Kunju LP, Bhalla R et al (2013) Accuracy of determining small renal mass management with risk stratified biopsies: confirmation by final pathology. J Urol 189(2):441–446CrossRefPubMed
17.
Zurück zum Zitat Fergany AF, Hafez KS, Novick AC (2000) Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup. J Urol 163:442–445CrossRefPubMed Fergany AF, Hafez KS, Novick AC (2000) Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup. J Urol 163:442–445CrossRefPubMed
18.
Zurück zum Zitat Stephenson AJ, Chetner MP, Rourke K et al (2004) Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J Urol 172:58–62CrossRefPubMed Stephenson AJ, Chetner MP, Rourke K et al (2004) Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J Urol 172:58–62CrossRefPubMed
Metadaten
Titel
Perioperative morbidity, oncological outcomes and predictors of pT3a upstaging for patients undergoing partial nephrectomy for cT1 tumors
verfasst von
Pascal Mouracade
Onder Kara
Julien Dagenais
M. J. Maurice
R. J. Nelson
Ercan Malkoc
J. H. Kaouk
Publikationsdatum
14.02.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 9/2017
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-017-2004-x

Weitere Artikel der Ausgabe 9/2017

World Journal of Urology 9/2017 Zur Ausgabe

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.